Thursday 16 October, 2025
Objectives: The compound S is a drug under development at Servier. It has poor water solubility and its PK profile in…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Application of Physiologically-Based Pharmacokinetic model To Predict Tramadol Concentration in human Milk
Thursday 16 October, 2025
Objectives: To use a Physiologically-Based Pharmacokinetic (PBPK) model for prediction of Tramadol milk concentration in mothers with different CYP2D6 Phenotypes. Methods: A…
Read moreOrder in patch absorption rates?
Thursday 16 October, 2025
Objectives: Transdermal delivery systems (“patch”) achieve steady “infusion-like” delivery avoiding sharp peaks & first pass metabolism, eliminating multiple dosing, increasing…
Read moreSelecting in vitro dissolution tests using population pharmacokinetic modelling to help bioequivalence studies
Thursday 16 October, 2025
Objectives: Before conducting bioequivalence (BE) studies or any related pilot studies for in vivo clinical trials, selecting an appropriate in…
Read morePhysiologically-based pharmacokinetic modelling of basmisanil to evaluate CYP3A mediated victim and perpetrator drug-drug interaction propensity
Thursday 16 October, 2025
Objectives: Basmisanil is a potent and highly selective GABAA-α5 receptor negative allosteric modulator [1]. Basmisanil has been investigated in different…
Read moreVirtual Bioequivalence Assessment of Two Tramadol Formulations using the Advanced Dissolution Absorption and Metabolism (ADAM) model via Simcyp R Package
Thursday 16 October, 2025
Objectives: A qualified PBPK model of tramadol has previously been used to simulate virtual bioequivalence (BE) trials using a random error…
Read moreOn the unphysical hypotheses in pharmacokinetics and oral drug absorption:Time to utilize instantaneous rate coefficients instead of rate constants
Thursday 16 October, 2025
Objectives: i) examine the homogeneity hypothesis using Monte Carlo simulations for a reaction and a diffusional process, which take place…
Read morePhysiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis
Thursday 16 October, 2025
Introduction: 5-flucytosine (5FC) is used for the treatment of cryptococcal meningoencephalitis (CM). Due to its short plasma half-life and safety…
Read morePhysiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children
Thursday 16 October, 2025
Administration of antiretroviral (ARV) drugs via MAPs has the potential to increase compliance and acceptability of HIV treatment for children….
Read morePhysiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation in the treatment of cryptococcal meningoencephalitis.
Thursday 16 October, 2025
Objectives: 5-flucytosine (5FC) is used for the treatment of cryptococcal meningoencephalitis in patients with advanced HIV. Currently, an immediate release…
Read more